Akari Therapeutics (NASDAQ:AKTX) (NASDAQ:AKTX) is a clinical-stage biopharmaceutical company focused on developing targeted therapies that modulate the complement system to treat rare and severe immune-mediated diseases. Leveraging proprietary protein-engineering capabilities, the company’s lead candidate, nomacopan, is a small recombinant protein designed to inhibit complement C5 and leukotriene B4. Nomacopan has been evaluated in multiple clinical trials across a range of indications, including paroxysmal nocturnal hemoglobinuria (PNH), hematopoietic stem cell transplant–associated thrombotic microangiopathy (HSCT-TMA) and bullous pemphigoid, reflecting Akari’s strategic emphasis on orphan and high-unmet-need markets.
Founded in 2009 and headquartered in London, United Kingdom, Akari Therapeutics operates research and development facilities in both the UK and the United States. The company has established regulatory interactions with agencies in Europe, North America and Asia, supporting an efficient global development program. In addition to nomacopan, Akari is advancing early-stage discovery programs targeting other components of the complement cascade, seeking to broaden its pipeline with novel biologics aimed at inflammatory and autoimmune disorders.
Akari’s management team combines deep expertise in complement biology and drug development. Jill Wigginton, President and Chief Executive Officer, has led the company through key clinical milestones and strategic partnerships. The broader leadership team includes seasoned executives in regulatory affairs, clinical operations and manufacturing, enabling Akari to navigate complex trials and scale its biologics platform. Akari’s board of directors features industry veterans and scientific advisors who guide the company’s long-term vision and ensure alignment with patient needs.
As Akari Therapeutics advances its clinical programs, the company remains committed to delivering transformative treatments for patients with limited therapeutic options. By harnessing a targeted approach to complement modulation, Akari aims to address critical gaps in care for rare hematologic and inflammatory diseases while building a diversified pipeline of next-generation protein therapeutics.
